While the precise regulatory mechanisms governing EMX2 expression in ESCC remain unclear, epigenetic modifications such as promoter methylation and histone modifications may play a role, as suggested by studies in esophageal, glioblastoma, and ovarian cancers [12,21,27]. This evidence concerns the gene EMX2 and ovarian carcinoma.